Types of Hair Restoration Procedures: A Complete Comparison

Hair restoration encompasses a wide spectrum of surgical and non-surgical interventions, ranging from follicular transplantation techniques to topical pharmacotherapy and energy-based devices. Understanding how these categories differ — by mechanism, candidacy requirements, safety profile, and expected outcome — is foundational to any informed evaluation. This page provides a structured, reference-grade comparison of the major procedure types recognized in clinical and regulatory practice, drawing on published standards from U.S. regulatory bodies and medical specialty organizations.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps
• Reference Table or Matrix

Definition and Scope

Hair restoration procedures are medical interventions designed to reverse, halt, or cosmetically compensate for hair loss across the scalp or other body areas. The U.S. Food and Drug Administration (FDA) regulates this space through two distinct pathways: drugs (evaluated under the Federal Food, Drug, and Cosmetic Act) and devices (cleared or approved via the 510(k) pathway or Premarket Approval). Surgical procedures themselves are not directly regulated by the FDA as a product category but fall under the jurisdiction of state medical boards and facility accreditation standards.

The scope of recognized hair restoration modalities includes: follicular unit transplantation (FUT), follicular unit extraction (FUE), robotic-assisted harvesting systems, platelet-rich plasma (PRP) therapy, low-level laser therapy (LLLT), scalp micropigmentation (SMP), and pharmaceutical agents including minoxidil and finasteride. The International Society of Hair Restoration Surgery (ISHRS) publishes practice standards and outcome data that serve as a primary reference point for classifying these procedures clinically.

For a broader overview of how these modalities are positioned within the field, the hair restoration resource index provides orientation across procedure types and related topics.

Core Mechanics or Structure

Each procedure category operates through a distinct physiological or cosmetic mechanism.

Follicular Unit Transplantation (FUT) involves surgically excising a linear strip of scalp tissue — typically from the occipital region — and dissecting it under stereomicroscopic magnification into individual follicular units of 1–4 hairs each. These grafts are then implanted into recipient sites at the thinning or bald area. The linear donor wound is closed with sutures or staples, leaving a single horizontal scar.

Follicular Unit Extraction (FUE) harvests individual follicular units directly from the donor scalp using a circular punch instrument ranging from 0.6 mm to 1.0 mm in diameter. No linear incision is made, which eliminates the linear scar but distributes small circular puncture marks across the donor zone. Both FUT and FUE are described in detail in the follicular unit extraction guide and follicular unit transplantation guide.

Robotic systems such as the ARTAS platform — FDA-cleared under the 510(k) pathway — use image-guided robotics to automate the FUE punch process. The ARTAS system received initial FDA clearance in 2011 (510(k) K103852). Automation introduces consistent punch depth and angulation but does not eliminate the need for physician oversight.

Platelet-Rich Plasma (PRP) therapy involves centrifuging autologous blood to concentrate growth factors including platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF), then injecting the concentrate into the scalp. The mechanism is believed to stimulate follicular progenitor cells, though the FDA has not cleared or approved PRP as a standalone hair loss treatment — it is used off-label.

Low-Level Laser Therapy (LLLT) devices deliver red light in the 630–670 nanometer wavelength range to the scalp. The FDA has cleared multiple LLLT devices for hair growth under the 510(k) pathway, including the HairMax LaserComb (cleared 2007). The proposed mechanism involves photobiomodulation of mitochondrial activity in follicular cells.

Scalp Micropigmentation (SMP) is a cosmetic tattooing technique that deposits pigment into the upper dermis to simulate the appearance of hair follicles or add density to thinning areas. It does not restore biological hair growth and is regulated as a cosmetic tattooing procedure under state jurisdiction, not FDA drug or device authority.

Pharmaceutical agents — specifically minoxidil (FDA-approved topical, first approved 1988) and finasteride (FDA-approved oral 1 mg tablet, approved 1997 under the brand name Propecia) — work through distinct pharmacological pathways. Minoxidil functions as a potassium channel opener that prolongs the anagen (growth) phase; finasteride inhibits 5-alpha-reductase type II, reducing dihydrotestosterone (DHT) levels by approximately 60–70% (FDA prescribing information, Propecia NDA 020788).

Causal Relationships or Drivers

The appropriateness of any procedure is driven by the underlying etiology of hair loss. Androgenetic alopecia — the most prevalent form, affecting an estimated 50 million men and 30 million women in the United States according to the American Academy of Dermatology (AAD) — responds to both pharmacological and surgical intervention because the follicles in the donor zone retain DHT resistance.

Scarring alopecias, including lichen planopilaris and frontal fibrosing alopecia, present a contraindication for most transplant procedures unless the underlying inflammatory process has been quiescent for a sustained period, as active inflammation destroys grafted follicles. The regulatory context for hair restoration page addresses how FDA oversight interacts with physician decision-making in these clinically variable cases.

Alopecia areata, an autoimmune-mediated condition, is generally not addressed by surgical transplantation during active disease phases. Traction alopecia and burn or trauma-related scarring may be candidates for surgical repair, but outcomes depend heavily on residual follicular density and scar tissue quality.

Classification Boundaries

Procedures are most usefully classified along three axes:

1. Biological vs. cosmetic: FUT, FUE, PRP, LLLT, and pharmaceuticals aim to restore or preserve biological hair growth. SMP is exclusively cosmetic.
2. Surgical vs. non-surgical: FUT and FUE are surgical procedures requiring local anesthesia and sterile operative conditions. PRP, LLLT, SMP, and pharmaceuticals are non-surgical.
3. Permanent vs. temporary: Surgical hair transplantation produces permanent redistribution of permanent follicles. Pharmaceutical effects persist only with continued use; cessation of minoxidil leads to shedding of drug-maintained hairs within 3–6 months.

The ISHRS further distinguishes procedures by graft yield potential: FUT typically yields 2,000–4,000+ grafts per session, while FUE per-session yield is generally lower due to donor density limitations and procedural time constraints.

Tradeoffs and Tensions

The central tension in surgical hair restoration is between donor supply and recipient demand. The scalp contains a finite number of DHT-resistant follicles in the safe donor zone — an area defined anatomically by studies including those published in the Dermatologic Surgery journal. Progressive hair loss can outpace the available donor supply, making early-stage surgery in young patients with unpredictable loss patterns a contested clinical decision.

FUT versus FUE presents a tradeoff between scar type and graft volume. FUT produces a linear scar that restricts very short hairstyles but may yield denser grafts with lower transection rates. FUE avoids the linear scar but distributes extraction across a wider donor area, potentially exhausting the safe zone more quickly in patients who require multiple sessions.

LLLT evidence remains contested. A 2014 randomized controlled trial published in the American Journal of Clinical Dermatology demonstrated statistically significant improvement in hair count with an FDA-cleared device, but effect sizes are modest and patient response is variable.

PRP lacks standardized protocols: centrifugation speed, platelet concentration, injection volume, and session frequency vary widely across practitioners, which complicates comparative outcome assessment. The absence of a standardized preparation protocol is acknowledged in the AAD's published literature on PRP.

Combining medical and surgical approaches — described in combining medical and surgical hair restoration — is increasingly standard practice, but the sequencing and interaction effects require individualized clinical judgment.

Common Misconceptions

Misconception: Hair transplants create new hair. Transplantation relocates existing follicles from one site to another. No new follicles are generated; the total follicular count in the scalp does not increase.

Misconception: FUE leaves no scarring. FUE leaves punctate scars across the donor zone. These are less visible than the FUT linear scar but are present and can become visible if the donor area is overharvested or the patient shaves the scalp.

Misconception: LLLT devices all perform equivalently. FDA clearance is device-specific and based on individual 510(k) submissions. Cleared devices differ in wavelength, energy density, and application method. One device's clearance does not extend to similar-appearing products.

Misconception: Finasteride is approved for women. The FDA has approved finasteride 1 mg (Propecia) only for men with androgenetic alopecia. Use in women — particularly women of childbearing potential — carries specific risk warnings detailed in the FDA-approved prescribing label (NDA 020788).

Misconception: PRP is an FDA-approved hair loss treatment. PRP devices (centrifuges) may be FDA-cleared as class II medical devices for general blood processing, but PRP injection for hair loss is not an FDA-approved indication.

Checklist or Steps

The following sequence reflects the standard evaluation and procedural framework recognized by the ISHRS and AAD for surgical hair restoration. This is a descriptive framework, not clinical guidance.

1. Etiology confirmation — Diagnosis of hair loss type via scalp examination, trichoscopy, or biopsy to confirm suitability for restoration.
2. Candidacy assessment — Evaluation of donor density, recipient area extent, age, and loss progression pattern using standardized scales such as the Norwood Scale for men or the Ludwig Scale for women.
3. Procedure selection — Determination of surgical method (FUT vs. FUE vs. robotic), adjunct therapies (PRP, LLLT), or pharmaceutical protocol based on diagnosis.
4. Pre-procedure preparation — Completion of medical history review, cessation of anticoagulant medications per physician direction, scalp preparation (pre-procedure preparation detail).
5. Procedure execution — Administration of local anesthesia, donor harvesting, graft preparation under magnification, and recipient site creation.
6. Post-procedure monitoring — Assessment for immediate complications including infection, folliculitis, or shock loss; management of graft survival conditions.
7. Recovery tracking — Structured follow-up at defined intervals; shed phase typically occurs within weeks 2–8 (recovery timeline).
8. Long-term outcome evaluation — Assessment of final results at 12–18 months post-procedure; determination of whether additional sessions are warranted.

Reference Table or Matrix

References

• U.S. Food and Drug Administration — Drug Approvals and Databases
• FDA Propecia (Finasteride 1 mg) Prescribing Information, NDA 020788
• FDA 510(k) Premarket Notification Database
• International Society of Hair Restoration Surgery (ISHRS)
• American Academy of Dermatology — Hair Loss Causes and Treatments
• FDA — Medical Device Classification and 510(k) Process
• National Library of Medicine — PubMed: Hair Restoration Clinical Literature

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)